Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer, March 2022

Free Subscription


Abstracts

Retrieve all available abstracts of the following 262 articles:
HTML format


 

Single Articles

  1. REIS IB, Tibo LHS, Socca EAR, de Souza BR, et al
    OncoTherad(R) (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway.
    Tissue Cell. 2022;76:101762.
    PubMed    
    Abstract available

  2. KIM JH, Choi J, Kim M, Kang SJ, et al
    Immunotherapeutic effects of recombinant Bacillus Calmette-Guerin containing sic gene in ex vivo and in vivo bladder cancer models.
    Investig Clin Urol. 2022;63:228-237.
    PubMed    
    Abstract available

  3. CHOI SY, Ha MS, Kim JH, Chi BH, et al
    Low-dose versus standard-dose bacille Calmette-Guerin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials.
    Investig Clin Urol. 2022;63:140-150.
    PubMed    
    Abstract available

  4. HADJI M, Rashidian H, Marzban M, Naghibzadeh-Tahami A, et al
    Opium use and risk of bladder cancer: a multi-centre case-referent study in Iran.
    Int J Epidemiol. 2022 Mar 4. pii: 6542534. doi: 10.1093.
    PubMed    
    Abstract available

  5. HENTSCHEL AE, Blankvoort CJ, Bosschieter J, Vis AN, et al
    Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non-muscle-invasive Bladder Cancer.
    Eur Urol Open Sci. 2022;37:7-13.
    PubMed    
    Abstract available

  6. LI X, Yang L, Huang W, Jia B, et al
    Immunological significance of alternative splicing prognostic signatures for bladder cancer.
    Heliyon. 2022;8:e08994.
    PubMed    
    Abstract available

  7. ZHU J, Lu Z, Chen W, Ke M, et al
    Systematic review and meta-analysis on laparoscopic cystectomy in bladder cancer.
    Transl Androl Urol. 2022;11:67-78.
    PubMed    
    Abstract available

  8. FAN X, Zou X, Liu C, Peng S, et al
    Global analysis of miRNA-mRNA regulation pair in bladder cancer.
    World J Surg Oncol. 2022;20:66.
    PubMed    
    Abstract available

  9. HAN Z, Gu J, Xin J, Liu H, et al
    Genetic variants in choline metabolism pathway are associated with the risk of bladder cancer in the Chinese population.
    Arch Toxicol. 2022 Mar 3. pii: 10.1007/s00204-022-03258.
    PubMed    
    Abstract available

  10. REN W, Zuo S, Yang L, Tu R, et al
    Identification of a novel immune-related long noncoding RNA signature to predict the prognosis of bladder cancer.
    Sci Rep. 2022;12:3444.
    PubMed    
    Abstract available

  11. LONATI C, Mordasini L, Afferi L, De Cobelli O, et al
    Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology - Young Academic Urologists.
    Urol Oncol. 2022 Feb 27. pii: S1078-1439(22)00003.
    PubMed    
    Abstract available

  12. ZHAN X, Chen L, Jiang M, Fu B, et al
    Trends in the cause of death among patients with bladder cancer in the US SEER population, 1992-2018.
    World J Urol. 2022 Mar 2. pii: 10.1007/s00345-022-03971.
    PubMed    
    Abstract available

  13. STOMP-AGENANT M, van Dijk T, Onur AR, Grimbergen MCM, et al
    In vivo Raman spectroscopy for bladder cancer detection using a superficial Raman probe compared to a non-superficial Raman probe.
    J Biophotonics. 2022 Mar 1:e202100354. doi: 10.1002/jbio.202100354.
    PubMed    
    Abstract available

  14. CAZENAVE L, Faucher M, Tourret M, Marques M, et al
    Intravenous lidocaine and cancer outcomes after radical cystectomy.
    Eur J Anaesthesiol. 2022;39:396-399.
    PubMed    


  15. DUTTA EK, Lewis MG, Albert S
    Risk factors associated with gall bladder cancer in high incidence areas in India: a systematic review protocol.
    BMJ Open. 2022;12:e056849.
    PubMed    
    Abstract available

  16. GARCIA-PERDOMO HA, Sanchez AL, Spiess PE
    Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review.
    Urol Oncol. 2022 Feb 26. pii: S1078-1439(22)00038.
    PubMed    
    Abstract available

  17. REBHAN K, Gust KM
    [Erratum to: Locally advanced or oligometastatic bladder cancer-role of local treatment of the primary tumor and metastases].
    Urologe A. 2022 Mar 1. pii: 10.1007/s00120-022-01789.
    PubMed    
    Abstract available

  18. RANGSITRATKUL C, Lawson C, Bernier-Godon F, Niavarani SR, et al
    Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer.
    Mol Ther Oncolytics. 2022;24:507-521.
    PubMed    
    Abstract available

  19. JAHANGIRIAN E, Jamal GA, Nouroozi M, Mohammadpour A, et al
    A Novel Multiepitope Vaccine Against Bladder Cancer Based on CTL and HTL Epitopes for Induction of Strong Immune Using Immunoinformatics Approaches.
    Int J Pept Res Ther. 2022;28:71.
    PubMed    
    Abstract available

  20. TABER A, Prip F, Lamy P, Agerbaek M, et al
    Immune Contexture and Differentiation Features Predict Outcome in Bladder Cancer.
    Eur Urol Oncol. 2022 Feb 25. pii: S2588-9311(22)00009.
    PubMed    
    Abstract available

  21. LIEDBERG F, Kjellstrom S, Lind AK, Sherif A, et al
    Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma.
    Scand J Urol. 2022 Feb 28:1-10. doi: 10.1080/21681805.2022.2041086.
    PubMed    
    Abstract available

  22. YANG F, Liu XQ, He JZ, Xian SP, et al
    Occludin facilitates tumour angiogenesis in bladder cancer by regulating IL8/STAT3 through STAT4.
    J Cell Mol Med. 2022 Feb 27. doi: 10.1111/jcmm.17257.
    PubMed    
    Abstract available

  23. HU R, Tao T, Yu L, Ding Q, et al
    Multi-Omics Characterization of Tumor Microenvironment Heterogeneity and Immunotherapy Resistance Through Cell States-Based Subtyping in Bladder Cancer.
    Front Cell Dev Biol. 2022;9:809588.
    PubMed    
    Abstract available

  24. YI R, Hong S, Zhang Y, Lin A, et al
    MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer.
    Front Cell Dev Biol. 2022;10:757137.
    PubMed    
    Abstract available

  25. EL AHANIDI H, El Azzouzi M, Hafidi Alaoui C, Tetou M, et al
    Immune Checkpoint and Telomerase Crosstalk Is Mediated by miRNA-138 in Bladder Cancer.
    Front Oncol. 2022;11:795242.
    PubMed    
    Abstract available

  26. ALVAREZ-MAESTRO M, Chierigo F, Mantica G, Quesada-Olarte JM, et al
    The effect of neoadjuvant chemotherapy among patients undergoing radical cystectomy for variant histology bladder cancer: A systematic review.
    Arab J Urol. 2021;20:1-13.
    PubMed    
    Abstract available

  27. SU G, Yao L, Han X, Liao X, et al
    A synthetic targeted RNA demethylation system based on CRISPR-Cas13b inhibits bladder cancer progression.
    Clin Transl Med. 2022;12:e734.
    PubMed    


  28. HELTE E, Save-Soderbergh M, Ugge H, Fall K, et al
    Chlorination by-products in drinking water and risk of bladder cancer - A population-based cohort study.
    Water Res. 2022;214:118202.
    PubMed    
    Abstract available

  29. LI G, Tao T, Deng D, Zhang S, et al
    Collagen-targeted tumor-specific transepithelial penetration enhancer mediated intravesical chemoimmunotherapy for non-muscle-invasive bladder cancer.
    Biomaterials. 2022;283:121422.
    PubMed    
    Abstract available

  30. BROUGHTON EI, Gooden KM, Mycock KL, Rajkovic I, et al
    Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
    BMC Urol. 2022;22:27.
    PubMed    
    Abstract available

  31. LONATI C, Afferi L, Mari A, Minervini A, et al
    Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration.
    World J Urol. 2022 Feb 26. pii: 10.1007/s00345-022-03958.
    PubMed    
    Abstract available

  32. HOU J, Liang S, Xie Z, Qu G, et al
    An immune-related lncRNA model for predicting prognosis, immune landscape and chemotherapeutic response in bladder cancer.
    Sci Rep. 2022;12:3225.
    PubMed    
    Abstract available

  33. KOTHA NV, Kumar A, Nelson TJ, Qiao EM, et al
    Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer.
    Urol Oncol. 2022 Feb 22. pii: S1078-1439(22)00028.
    PubMed    
    Abstract available

  34. CIMADAMORE A, Lonati C, Di Trapani E, De Cobelli O, et al
    Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?
    Urol Oncol. 2022 Feb 22. pii: S1078-1439(22)00026.
    PubMed    
    Abstract available

  35. LIN CH, Chang HH, Lai CR, Wang HH, et al
    Fatty Acid Binding Protein 6 Inhibition Decreases Cell Cycle Progression, Migration and Autophagy in Bladder Cancers.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  36. VENKATRAMANI V, Reis IM, Gonzalgo ML, Castle EP, et al
    Comparison of Robot-Assisted and Open Radical Cystectomy in Recovery of Patient-Reported and Performance-Related Measures of Independence: A Secondary Analysis of a Randomized Clinical Trial.
    JAMA Netw Open. 2022;5:e2148329.
    PubMed    
    Abstract available

  37. SINGHAL S, Ruprecht NA, Sens D, Tavakolian K, et al
    Association between Arsenic Level, Gene Expression in Asian Population, and In Vitro Carcinogenic Bladder Tumor.
    Oxid Med Cell Longev. 2022;2022:3459855.
    PubMed    
    Abstract available

  38. OLKHOV-MITSEL E, Hodgson A, Liu SK, Vesprini D, et al
    Upregulation of IFN-mediated chemokines dominate the immune transcriptome of muscle-invasive urothelial carcinoma.
    Sci Rep. 2022;12:716.
    PubMed    
    Abstract available

  39. MA C, Wang J, Zhao N, Pan Z, et al
    Network Pharmacology-Based Study on the Active Component and Mechanism of the Anti-Non-Invasive and Invasive Bladder Urothelial Carcinoma Effects of Zhuling Jisheng Decoction.
    Comput Math Methods Med. 2021;2021:7667707.
    PubMed    
    Abstract available

  40. JIN HJ, Shim JS, Kwon TG, Kim TH, et al
    Gender-related outcomes in robot-assisted radical cystectomy: A multi-institutional study.
    Investig Clin Urol. 2022;63:53-62.
    PubMed    
    Abstract available

  41. LEE K, Jeong SH, Yoo SH, Ku JH, et al
    Evaluating the efficacy of secondary transurethral resection of the bladder for high-grade Ta tumors.
    Investig Clin Urol. 2022;63:14-20.
    PubMed    
    Abstract available

  42. CHAN TC, Chen YT, Tan KT, Wu CL, et al
    Biological significance of MYC and CEBPD coamplification in urothelial carcinoma: Multilayered genomic, transcriptional and posttranscriptional positive feedback loops enhance oncogenic glycolysis.
    Clin Transl Med. 2021;11:e674.
    PubMed    
    Abstract available

  43. PEHALOVA L, Krejci D, Buchler T, Janosek J, et al
    Incidence, mortality and survival of bladder neoplasms in the Czech Republic in the period 1977-2017: a time trend analysis.
    Klin Onkol. 2021;34:467-476.
    PubMed    
    Abstract available

  44. KOBAYASHI S, Ito M, Takemura K, Suzuki H, et al
    Preoperative models incorporating the systemic immune-inflammation index for predicting prognosis and muscle invasion in patients with non-metastatic upper tract urothelial carcinoma.
    Int J Clin Oncol. 2022;27:574-584.
    PubMed    
    Abstract available

  45. MATSUMURA T, Inoue K, Toyooka K, Inoue M, et al
    Clinical trajectory of a patient with filaminopathy who developed arrhythmogenic cardiomyopathy, myofibrillar myopathy, and multiorgan tumors.
    Neuromuscul Disord. 2021;31:1282-1286.
    PubMed    
    Abstract available

  46. ZAKI SA, Hazeem AA, Rashid A
    Bacillus Calmette-Guerin scar reactivation in multisystem inflammatory syndrome in children.
    Trop Doct. 2022;52:222-223.
    PubMed    


  47. TURAL D, Selcukbiricik F, Olmez OF, Sumbul AT, et al
    Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma.
    Int J Clin Oncol. 2022;27:585-591.
    PubMed    
    Abstract available

  48. DA SILVA GOMES PR, Candido P, Ghazarian V, Camargo JA, et al
    Can increased expression of miR-Let-7c reduce the transition potential of high-grade urothelial carcinoma?
    Mol Biol Rep. 2021;48:7947-7952.
    PubMed    
    Abstract available

  49. GUPTA P, Kumar N, Garg M
    Emerging roles of autophagy in the development and treatment of urothelial carcinoma of the bladder.
    Expert Opin Ther Targets. 2021;25:787-797.
    PubMed    
    Abstract available

  50. LIEDBERG F
    Adjuvant checkpoint inhibition after cystectomy - why, when, and for whom?
    Scand J Urol. 2022;56:73-74.
    PubMed    


  51. ALI D, Sawhney R, Billah M, Harrison R, et al
    Single-Port Robotic Radical Cystectomy with Intracorporeal Bowel Diversion: Initial Experience and Review of Surgical Outcomes.
    J Endourol. 2022;36:216-223.
    PubMed    
    Abstract available

  52. NIELSEN MO, Elversang J, Martin Poulsen A, Persson Theilgaard Z, et al
    A case of visible diffuse peritoneal Bacillus Calmette-Guerin infection at the time of planned radical cystectomy.
    Scand J Urol. 2021;55:505-506.
    PubMed    


  53. NISHIYAMA N, Kobayashi T, Narita S, Hidaka Y, et al
    Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching.
    J Geriatr Oncol. 2022;13:88-93.
    PubMed    
    Abstract available

  54. SERAG ELDIEN MM, Abdou AG, Elghrabawy GRA, Alhanafy AM, et al
    Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5/6.
    J Immunoassay Immunochem. 2021;42:662-678.
    PubMed    
    Abstract available

  55. VENKATRAMANI V, Parekh DJ
    Surgery for Bladder and Upper Tract Urothelial Cancer.
    Hematol Oncol Clin North Am. 2021;35:543-566.
    PubMed    
    Abstract available

  56. NADAL R, Clara JA, Valderrama BP, Bellmunt J, et al
    Current Therapy for Metastatic Urothelial Carcinoma.
    Hematol Oncol Clin North Am. 2021;35:469-493.
    PubMed    
    Abstract available

  57. JENSEN JB
    Patients with NMIBC with the highest risk of progression are correctly selected for cystectomy in Sweden.
    Scand J Urol. 2021;55:54-55.
    PubMed    


  58. HEMDAN T, Einarsson R, Malmstrom PU
    The new classification of urinary cytology - is it an improvement?
    Scand J Urol. 2021;55:98-99.
    PubMed    


  59. ZHANG X, Wei X, Qi J, Shen J, et al
    Simultaneous Detection of Bladder Cancer Exosomal MicroRNAs Based on Inorganic Nanoflare and DNAzyme Walker.
    Anal Chem. 2022 Mar 11. doi: 10.1021/acs.analchem.1c05588.
    PubMed    
    Abstract available

  60. TEODOROVICH OV, Shatokhin MN, Kholimenko IM, Abdullaev MI, et al
    [Application of laser technologies in the treatment of non-muscle-invasive bladder cancer].
    Urologiia. 2022;:89-95.
    PubMed    
    Abstract available

  61. NIK AB KADIR MN, Hairon SM, Yaacob NM, Ab Manan A, et al
    Prognostic Factors for Bladder Cancer Patients in Malaysia: A Population-Based Study.
    Int J Environ Res Public Health. 2022;19.
    PubMed    
    Abstract available

  62. HOEH B, Flammia RS, Hohenhorst L, Sorce G, et al
    Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  63. JACYNA J, Kordalewska M, Artymowicz M, Markuszewski M, et al
    Pre- and Post-Resection Urine Metabolic Profiles of Bladder Cancer Patients: Results of Preliminary Studies on Time Series Metabolomics Analysis.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  64. GONZALEZ-DEL-ALBA A, Conde-Moreno AJ, Garcia Vicente AM, Gonzalez-Peramato P, et al
    Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  65. OZLER S, Pazarci P
    Anti-tumoral effect of beta-blockers on prostate and bladder cancer cells via mitogen-activated protein kinase pathways.
    Anticancer Drugs. 2022;33:384-388.
    PubMed    
    Abstract available

  66. MULAWKAR PM, Sharma G, Tamhankar A, Shah U, et al
    Role of Macroscopic Image Enhancement in Diagnosis of Non-Muscle-Invasive Bladder Cancer: An Analytical Review.
    Front Surg. 2022;9:762027.
    PubMed    
    Abstract available

  67. SONG X, Xin S, Zhang Y, Mao J, et al
    Identification and Quantification of Iron Metabolism Landscape on Therapy and Prognosis in Bladder Cancer.
    Front Cell Dev Biol. 2022;10:810272.
    PubMed    
    Abstract available

  68. LUO Y, Tao T, Tao R, Huang G, et al
    Single-Cell Transcriptome Comparison of Bladder Cancer Reveals Its Ecosystem.
    Front Oncol. 2022;12:818147.
    PubMed    
    Abstract available

  69. ALANEE S, El-Zawahry A
    Robotic-Assisted Partial Cystectomy for Muscle Invasive Bladder Cancer: Contemporary Experience.
    Int J Med Robot. 2022 Mar 8:e2390. doi: 10.1002/rcs.2390.
    PubMed    
    Abstract available

  70. NERONI B, Zingaropoli MA, Radocchia G, Ciardi MR, et al
    Evaluation of the anti-proliferative activity of violacein, a natural pigment of bacterial origin, in urinary bladder cancer cell lines.
    Oncol Lett. 2022;23:132.
    PubMed    
    Abstract available

  71. NISHIHARA K, Ueda K, Kurose H, Ogasawara N, et al
    Survival outcomes of non-definitive therapy for muscle-invasive bladder cancer.
    Oncol Lett. 2022;23:126.
    PubMed    
    Abstract available

  72. IYA AM, Beyer K, Kotecha P, Kibaru J, et al
    Scoping review: bladder cancer in Nigeria - what are the gaps in clinical care and research?
    BMJ Open. 2022;12:e049241.
    PubMed    
    Abstract available

  73. KANO K, Ishiyama R, Yagisawa T, Odani K, et al
    [Primary Carcinoid Tumor of the Urinary Bladder : A Case Report].
    Hinyokika Kiyo. 2022;68:53-57.
    PubMed    
    Abstract available

  74. BELLUT L, Kunath F
    [Blue versus white light for transurethral resection of non-muscle invasive bladder cancer (Review)].
    Urologe A. 2022 Mar 8. pii: 10.1007/s00120-022-01790.
    PubMed    


  75. POURKERMAN M, Rashidkhani B, Moslehi N
    Correlating Dietary Pattern and Bladder Cancer Risk Using Principal Component and Reduced Rank Regression Analyses.
    Nutr Cancer. 2022 Mar 7:1-9. doi: 10.1080/01635581.2022.2047739.
    PubMed    
    Abstract available

  76. NAKASATO T, Inoue T, Kato R, Nakagami Y, et al
    A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer.
    IJU Case Rep. 2021;5:92-94.
    PubMed    
    Abstract available

  77. DU H, Tao T, Xu S, Xu C, et al
    4-Methoxydalbergione Inhibits Bladder Cancer Cell Growth via Inducing Autophagy and Inhibiting Akt/ERK Signaling Pathway.
    Front Mol Biosci. 2022;8:789658.
    PubMed    
    Abstract available

  78. ZHAO J, Huang S, Tan D, Yang K, et al
    PGM1 and ENO1 Promote the Malignant Progression of Bladder Cancer via Comprehensive Analysis of the m6A Signature and Tumor Immune Infiltration.
    J Oncol. 2022;2022:8581805.
    PubMed    
    Abstract available

  79. PAPAETIS GS
    Pioglitazone, Bladder Cancer and the Presumption of Innocence.
    Curr Drug Saf. 2022 Mar 4. pii: CDS-EPUB-121335.
    PubMed    
    Abstract available

  80. TONYALI S
    Combining Clinical Parameters and Immunohistochemical Markers Might Strengthen Prediction of Recurrence of Non-Muscle Invasive Bladder Cancer.
    J Invest Surg. 2022 Mar 6:1-2. doi: 10.1080/08941939.2022.2047244.
    PubMed    


  81. BEIJE N, de Kruijff IE, de Jong JJ, Klaver SO, et al
    Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.
    ESMO Open. 2022;7:100416.
    PubMed    
    Abstract available

  82. LIU KL, Yin YW, Lu BS, Niu YL, et al
    E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter.
    Cancer Cell Int. 2022;22:109.
    PubMed    
    Abstract available

  83. XU D, Cao Q, Wang L, Wang J, et al
    A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer.
    Mol Cancer Ther. 2022 Feb 28. pii: 681956. doi: 10.1158/1535-7163.MCT-21-0613.
    PubMed    
    Abstract available

  84. WANG L, Hu C, Zhao Y, Hu X, et al
    Novel smac mimetic ASTX660 (Tolinapant) and TNF-alpha synergistically induce necroptosis in bladder cancer cells in vitro upon apoptosis inhibition.
    Biochem Biophys Res Commun. 2022;602:8-14.
    PubMed    
    Abstract available

  85. MOFID B, Razzaghdoust A, Ghajari M, Basiri A, et al
    The Oncological Outcomes of Neoadjuvant Gemcitabine plus Carboplatin versus Gemcitabine plus Cisplatin in Locally Advanced Bladder Cancer: A Retrospective Analysis.
    Urol J. 2022 Mar 5. pii: 6841. doi: 10.22037/uj.v19i.6841.
    PubMed    
    Abstract available

  86. PARAMANANTHAM Y, Chung I, Bm Said NA
    The role of tumour microenvironment-driven miRNAs in the chemoresistance of muscle-invasive bladder cancer-a review.
    Urol Oncol. 2022 Mar 1. pii: S1078-1439(22)00031.
    PubMed    
    Abstract available

  87. HAO J, Zhang W, Huang Z
    Bupivacaine modulates the apoptosis and ferroptosis in bladder cancer via phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
    Bioengineered. 2022;13:6794-6806.
    PubMed    
    Abstract available

  88. KAO CC, Chang YL, Liu HY, Wu ST, et al
    DNA Hypomethylation Is Associated with the Overexpression of INHBA in Upper Tract Urothelial Carcinoma.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  89. PATELLI G, Zeppellini A, Spina F, Righetti E, et al
    The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives.
    Cancer Treat Rev. 2022;104:102351.
    PubMed    
    Abstract available

  90. MARTINI A, Raggi D, Fallara G, Nocera L, et al
    Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis.
    Cancer Treat Rev. 2022;104:102360.
    PubMed    
    Abstract available

  91. IACOVINO ML, Miceli CC, De Felice M, Barone B, et al
    Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  92. OKAMATSU Y, Tsubouchi K, Iwasaki T, Nakamura T, et al
    Recurrent Massive Hemothorax of Unknown Etiology in an 85-Year-Old Man.
    Chest. 2022;161:e103-e110.
    PubMed    
    Abstract available

  93. ALTAHA MA, Tarulli M, Bajwa J, Mafeld S, et al
    Endovascular coil embolization of inferior mesenteric artery to ileal-conduit fistula: a case report.
    BMC Urol. 2022;22:11.
    PubMed    
    Abstract available

  94. ALLEN G
    A Systematic Review and Meta-Analysis of Enhanced Recovery After Surgery Protocols for Radical Cystectomy.
    AORN J. 2022;115:186-189.
    PubMed    


  95. ZHONG W, Yang M, Cheng S, Hou W, et al
    Identification of an IDO1-based immune classifier for survival prediction of upper tract urothelial carcinoma.
    Cancer Sci. 2022;113:852-863.
    PubMed    
    Abstract available

  96. YU J, Zheng J
    Comparative efficacy and safety of transurethral laser surgery with holmium laser, KTP laser, 2-micron laser or thulium laser for the treatment of non-muscle invasive bladder carcinoma: a protocol of network meta-analysis.
    BMJ Open. 2021;11:e055840.
    PubMed    
    Abstract available

  97. BAECKER D, Sagasser J, Karaman S, Hormann AA, et al
    Development of methylated cobalt-alkyne complexes with selective cytotoxicity against COX-positive cancer cell lines.
    Arch Pharm (Weinheim). 2022;355:e2100408.
    PubMed    
    Abstract available

  98. MEZA L, Malhotra J, Favorito C, Pal SK, et al
    Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma.
    Future Oncol. 2022;18:21-33.
    PubMed    
    Abstract available

  99. NORGAARD M, Andersen IT, Heide-Jorgensen U, Erichsen R, et al
    Ranitidine and Risk of Bladder and Kidney Cancer: A Population-Based Cohort Study.
    Cancer Epidemiol Biomarkers Prev. 2022;31:45-50.
    PubMed    
    Abstract available

  100. QUAQUARINI E, Saltalamacchia G, Tresoldi MM, Schmid M, et al
    Primary melanoma of the bladder: a case report and review of the literature.
    Eur Rev Med Pharmacol Sci. 2021;25:5122-5128.
    PubMed    
    Abstract available

  101. PAL SK, Frankel PH, Mortazavi A, Milowsky M, et al
    Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2021;7:1536-1543.
    PubMed    
    Abstract available

  102. COLLINS K, Alkashash AM, Hwang M, Kaimakliotis HZ, et al
    Somatic-Type Yolk Sac Tumor Arising as a Predominant Component of Bladder Urothelial Carcinoma.
    Int J Surg Pathol. 2022;30:207-213.
    PubMed    
    Abstract available

  103. GUPTA M, Sancheti S, Sali AP, Somal PK, et al
    Ectopic Prostate Tissue Presenting as Urinary Bladder Tumor: The Imitation Game!
    Int J Surg Pathol. 2022;30:160-162.
    PubMed    
    Abstract available

  104. ZHENG G, Sundquist K, Sundquist J, Forsti A, et al
    Bladder and upper urinary tract cancers as first and second primary cancers.
    Cancer Rep (Hoboken). 2021;4:e1406.
    PubMed    
    Abstract available

  105. SHASH LS, Ibrahim RA, Elgohary SA
    E-cadherin and N-cadherin Immunohistochemical Expression in Proliferating Urothelial Lesions: Potential Novel Cancer Predictive EMT Profiles.
    Appl Immunohistochem Mol Morphol. 2021;29:657-666.
    PubMed    
    Abstract available

  106. FUJIWARA M, Yuasa T, Urasaki T, Komai Y, et al
    Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan.
    Cancer Rep (Hoboken). 2021;4:e1398.
    PubMed    
    Abstract available

  107. KYRIAZOGLOU A, Beuselinck B
    Equivocal evaluation of progressive disease in patients treated with immune checkpoint inhibitors: a challenge for clinical trials and biomarker research.
    Acta Clin Belg. 2022;77:406-409.
    PubMed    
    Abstract available

  108. DELLI PIZZI A, Mastrodicasa D, Taraschi A, Civitareale N, et al
    Conspicuity and muscle-invasiveness assessment for bladder cancer using VI-RADS: a multi-reader, contrast-free MRI study to determine optimal b-values for diffusion-weighted imaging.
    Abdom Radiol (NY). 2022 Mar 18. pii: 10.1007/s00261-022-03490.
    PubMed    
    Abstract available

  109. COOK GS, Howard JM
    Patterns in the Management of Low-Grade Non-Muscle-Invasive Bladder Cancer-the Human and Economic Costs of Excessive Surveillance.
    JAMA Netw Open. 2022;5:e223055.
    PubMed    


  110. BREE KK, Shan Y, Hensley PJ, Lobo N, et al
    Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013.
    JAMA Netw Open. 2022;5:e223050.
    PubMed    
    Abstract available

  111. SHANGGUAN W, Hu J, Xie Y, Chen Z, et al
    Conditional survival of trimodal therapy for nonmetastatic muscle-invasive bladder cancer: A SEER database analysis.
    Cancer Med. 2022 Mar 18. doi: 10.1002/cam4.4625.
    PubMed    
    Abstract available

  112. ROUPRET M, Gontero P, McCracken SRC, Dudderidge T, et al
    Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker.
    Eur Urol Focus. 2022 Mar 14. pii: S2405-4569(22)00051.
    PubMed    
    Abstract available

  113. ZHONG Z, Huang M, Lv M, He Y, et al
    Corrigendum to "Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway" [Cancer Letter 403(2017) 305-317].
    Cancer Lett. 2022 Mar 14:215631. doi: 10.1016/j.canlet.2022.215631.
    PubMed    


  114. ZHANG M, Du G, Li Z, Li D, et al
    An Oxidative Stress-Related Genes Signature for Predicting Survival in Bladder Cancer: Based on TCGA Database and Bioinformatics.
    Int J Gen Med. 2022;15:2645-2667.
    PubMed    
    Abstract available

  115. LEMINSKI A, Kaczmarek K, Golab A, Kotfis K, et al
    Increased One-Year Mortality Among Elderly Patients After Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective, Observational Comparative Study.
    Clin Interv Aging. 2022;17:255-263.
    PubMed    
    Abstract available

  116. GHAFOURI-FARD S, Najafi S, Hussen BM, Basiri A, et al
    The Role of Circular RNAs in the Carcinogenesis of Bladder Cancer.
    Front Oncol. 2022;12:801842.
    PubMed    
    Abstract available

  117. YUAN Z, Guo G, Sun G, Li Q, et al
    Magnesium isoglycyrrhizinate suppresses bladder cancer progression by modulating the miR-26b/Nox4 axis.
    Bioengineered. 2022;13:7986-7999.
    PubMed    
    Abstract available

  118. MIAO L, Liu HY, Zhou C, He X, et al
    Correction to: LINC00612 enhances the proliferation and invasion ability of bladder cancer cells as ceRNA by sponging miR-590 to elevate expression of PHF14.
    J Exp Clin Cancer Res. 2022;41:103.
    PubMed    


  119. LI D, Zhen F, Le J, Chen G, et al
    Identification of hub genes and pathways in bladder cancer using bioinformatics analysis.
    Am J Clin Exp Urol. 2022;10:13-24.
    PubMed    
    Abstract available

  120. DALLA E, Picco R, Novara G, Moro FD, et al
    Identification of a gene signature for the prediction of recurrence and progression in non-muscle-invasive bladder cancer.
    Mol Biomed. 2022;3:9.
    PubMed    


  121. PAWAR D, Arif D, Raghunath A, Rehman S, et al
    Urothelial carcinoma with mandibular metastasis and synchronous prostate cancer.
    BMJ Case Rep. 2022;15.
    PubMed    
    Abstract available

  122. TELEKA S, Jochems SHJ, Jirstrom K, Stocks T, et al
    The interaction between smoking and bladder cancer genetic variants on urothelial cancer risk by disease aggressiveness.
    Cancer Med. 2022 Mar 13. doi: 10.1002/cam4.4654.
    PubMed    
    Abstract available

  123. WIECZOREK E, Farooqi AA, Reszka E
    Androgen receptor modulation and bladder cancer prevention - a short review.
    Med Pr. 2022 Mar 14. pii: 146548. doi: 10.13075/mp.5893.01229.
    PubMed    
    Abstract available

  124. MARTINI A, Raggi D, Marandino L, Montorsi F, et al
    The Paradoxical Role of Body Mass Index in Patients with Muscle-invasive Bladder Cancer Receiving Neoadjuvant Immunotherapy.
    Eur Urol Oncol. 2022 Mar 10. pii: S2588-9311(22)00030.
    PubMed    


  125. ELUMALAI T, Croxford W, Buijtenhuijs B, Conroy R, et al
    Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy.
    Clin Oncol (R Coll Radiol). 2022 Mar 10. pii: S0936-6555(22)00106.
    PubMed    
    Abstract available

  126. WANG W, Liu X, Zhang C, Sheng F, et al
    Identification of two-dimensional copper signatures in human blood for bladder cancer with machine learning.
    Chem Sci. 2022;13:1648-1656.
    PubMed    
    Abstract available

  127. SOIPI S, Vucic M, Spajic B, Kruslin B, et al
    REVIEW OF THE BLADDER CANCER MOLECULAR CLASSIFICATION PROPOSED: A NEW ERA - NEW TAXONOMY.
    Acta Clin Croat. 2022;60:519-524.
    PubMed    
    Abstract available

  128. CHEN W, Jiang T, Mao H, Gao R, et al
    Erratum: Nodal Promotes the Migration and Invasion of Bladder Cancer Cells via Regulation of Snail: Erratum.
    J Cancer. 2022;13:1385.
    PubMed    
    Abstract available

  129. TONG S, Yin H, Fu J, Li Y, et al
    Niban apoptosis regulator 1 promotes gemcitabine resistance by activating the focal adhesion kinase signaling pathway in bladder cancer.
    J Cancer. 2022;13:1103-1118.
    PubMed    
    Abstract available

  130. ZHAN X, Chen T, Jiang M, Deng W, et al
    A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Muscle-Invasive Bladder Cancer Patients after Partial Cystectomy.
    J Oncol. 2022;2022:2665711.
    PubMed    
    Abstract available

  131. DONG Y, Hao L, Shi ZD, Fang K, et al
    Solasonine Induces Apoptosis and Inhibits Proliferation of Bladder Cancer Cells by Suppressing NRP1 Expression.
    J Oncol. 2022;2022:7261486.
    PubMed    
    Abstract available

  132. YE L, Chen Y, Xu H, Wang Z, et al
    Radiomics of Contrast-Enhanced Computed Tomography: A Potential Biomarker for Pretreatment Prediction of the Response to Bacillus Calmette-Guerin Immunotherapy in Non-Muscle-Invasive Bladder Cancer.
    Front Cell Dev Biol. 2022;10:814388.
    PubMed    
    Abstract available

  133. HU J, Lai C, Shen Z, Yu H, et al
    A Prognostic Model of Bladder Cancer Based on Metabolism-Related Long Non-Coding RNAs.
    Front Oncol. 2022;12:833763.
    PubMed    
    Abstract available

  134. ZHONG Z, Wang Z, Li Y, Zhong Y, et al
    Sintilimab treatment for ureteral carcinoma following bladder cancer leads to leukopenia: a case report.
    Transl Androl Urol. 2022;11:277-284.
    PubMed    
    Abstract available

  135. LIU S, Yao Y, Guan F, Sun L, et al
    Neoadjuvant Chemotherapy for Different Stages of Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Dis Markers. 2022;2022:8493519.
    PubMed    
    Abstract available

  136. ZHOU R, Liang J, Tian H, Chen Q, et al
    An Immunosenescence-Related Gene Signature to Evaluate the Prognosis, Immunotherapeutic Response, and Cisplatin Sensitivity of Bladder Cancer.
    Dis Markers. 2022;2022:2143892.
    PubMed    
    Abstract available

  137. YAN R, Dai W, Wu R, Huang H, et al
    Therapeutic targeting m6A-guided miR-146a-5p signaling contributes to the melittin-induced selective suppression of bladder cancer.
    Cancer Lett. 2022;534:215615.
    PubMed    
    Abstract available

  138. KULCHAVENYA EV, Kholtobin DP, Telina EV, Neymark AI, et al
    [Practice of urological departments during the COVID-19 pandemic].
    Urologiia. 2022;:35-40.
    PubMed    
    Abstract available

  139. CAMPOBASSO D, Puliatti S, Micali S, Maestroni UV, et al
    Conservative treatment of upper urinary tract urothelial carcinoma (UTUC) in patients with imperative indications: not only an option.
    Minerva Urol Nephrol. 2022;74:129-130.
    PubMed    


  140. DEL GIUDICE F, Chung BI, Moschini M, Mari A, et al
    Comment on: Postoperative outcomes of Fast-Track-enhanced recovery protocol in open radical cystectomy: comparison with standard management in a high-volume center and Trifecta proposal.
    Minerva Urol Nephrol. 2022;74:119-121.
    PubMed    


  141. KIM MS, Koom WS, Cho JH, Kim SY, et al
    Optimal management of recurrent and metastatic upper tract urothelial carcinoma: Implications of intensity modulated radiation therapy.
    Radiat Oncol. 2022;17:51.
    PubMed    
    Abstract available

  142. XIONG S, Huang W, Liu X, Chen Q, et al
    Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma.
    Cell Transplant. 2022;31:9636897221077921.
    PubMed    
    Abstract available

  143. WANG Z, Zhao Y, Shen X, Zhao Y, et al
    Single-Cell Genomics-Based Molecular Algorithm for Early Cancer Detection.
    Anal Chem. 2022;94:2607-2614.
    PubMed    
    Abstract available

  144. PHRUTTINARAKORN B, Plumworasawat S, Kayankarnnavee J, Lualon J, et al
    Application of the Paris Reporting System for Urine Cytology: The Three-Year Experience of a Single Tertiary Care Institute in Thailand.
    Acta Cytol. 2022;66:134-141.
    PubMed    
    Abstract available

  145. LI P, Qiao G, Lu J, Ji W, et al
    PVT1 is a prognostic marker associated with immune invasion of bladder urothelial carcinoma.
    Math Biosci Eng. 2022;19:169-190.
    PubMed    
    Abstract available

  146. ROPERTO S
    Role of BAG3 in bovine Deltapapillomavirus-mediated autophagy.
    J Cell Biochem. 2022;123:59-64.
    PubMed    
    Abstract available

  147. STRUCK JP, Schnoor M, Schulze A, Hupe MC, et al
    Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitals.
    World J Urol. 2022;40:409-418.
    PubMed    
    Abstract available

  148. OSUMO B, Radzevich J, Nashed N, Ustwani O, et al
    Primary Parotid Non-Hodgkin's B-Cell Lymphoma in an Elderly Woman on Pembrolizumab for Metastatic Invasive Papillary Urothelial Cell Carcinoma of the Bladder.
    Am Surg. 2021 Nov 8:31348211054526. doi: 10.1177/00031348211054526.
    PubMed    
    Abstract available

  149. LI M, Xu X, Bechmann N, Pamporaki C, et al
    Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review.
    World J Urol. 2022;40:385-390.
    PubMed    
    Abstract available

  150. TARANTINO P, Modi S, Tolaney SM, Cortes J, et al
    Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review.
    JAMA Oncol. 2021;7:1873-1881.
    PubMed    
    Abstract available

  151. SUN K, Wang D, Wu G, Ma J, et al
    Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors.
    Cancer Med. 2021;10:7534-7541.
    PubMed    
    Abstract available

  152. WARD M, Albertson D, Furtado LV, Deftereos G, et al
    PD-L1 Tumor Cell Expression in Upper Tract Urothelial Carcinomas is Associated With Higher Pathologic Stage.
    Appl Immunohistochem Mol Morphol. 2022;30:56-61.
    PubMed    
    Abstract available

  153. AFFERI L, Abufaraj M, Soria F, D'Andrea D, et al
    A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis.
    Minerva Urol Nephrol. 2022;74:49-56.
    PubMed    
    Abstract available

  154. CEYLAN OM, Durukan AH, Uysal Y, Ozge G, et al
    Ocular Complications of Intravesicular BCG Treatment for Bladder Carcinoma.
    Ocul Immunol Inflamm. 2022;30:111-114.
    PubMed    
    Abstract available

  155. FENG F, Yang J, Chen A, Cui M, et al
    Long non-coding RNA long intergenic non-protein coding RNA 1232 promotes cell proliferation, migration and invasion in bladder cancer via modulating miR-370-5p/PIM3 axis.
    J Tissue Eng Regen Med. 2022 Mar 26. doi: 10.1002/term.3291.
    PubMed    
    Abstract available

  156. XU Y, Zeng H, Jin K, Liu Z, et al
    Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer.
    J Immunother Cancer. 2022;10.
    PubMed    
    Abstract available

  157. ROBERTS ME, Contreras-Sanz A, Black PC
    Establishing a Foundation for Studying the Immune Contexture Across the Spectrum of Bladder Cancer.
    Eur Urol Oncol. 2022 Mar 22. pii: S2588-9311(22)00032.
    PubMed    


  158. WILSON F, Joseph N, Choudhury A
    Biomarkers in muscle invasive bladder cancer.
    Adv Clin Chem. 2022;107:265-297.
    PubMed    
    Abstract available

  159. WIGNER P, Bijak M, Saluk-Bijak J
    Clinical Potential of Fruit in Bladder Cancer Prevention and Treatment.
    Nutrients. 2022;14.
    PubMed    
    Abstract available

  160. CLAPS F, Mir C, Rubio-Briones J
    Optimization of the different therapeutic strategies in muscle invasive bladder cancer using biomarkers.
    Arch Esp Urol. 2022;75:144-155.
    PubMed    
    Abstract available

  161. LOZANO F, Raventos CX, Carrion A, Trilla E, et al
    [Optimization biomarkers in the surveillance of non muscle invasive bladder cancer.]
    Arch Esp Urol. 2022;75:133-143.
    PubMed    
    Abstract available

  162. DOMINGUEZ ESCRIG JL, Rubio Briones J
    Urinary biomarkers for the optimization of bladder cancer screening.
    Arch Esp Urol. 2022;75:126-132.
    PubMed    
    Abstract available

  163. TAN Z, Fu S, Huang Y, Duan X, et al
    HSPB8 is a Potential Prognostic Biomarker that Correlates With Immune Cell Infiltration in Bladder Cancer.
    Front Genet. 2022;13:804858.
    PubMed    
    Abstract available

  164. AHN JH, Kang CK, Kim EM, Kim AR, et al
    Proteomics for Early Detection of Non-Muscle-Invasive Bladder Cancer: Clinically Useful Urine Protein Biomarkers.
    Life (Basel). 2022;12.
    PubMed    
    Abstract available

  165. ORTIZ-BONILLA CJ, Uccello TP, Gerber SA, Lord EM, et al
    Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  166. FERRO M, Tataru OS, Musi G, Lucarelli G, et al
    Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy.
    Diagnostics (Basel). 2022;12.
    PubMed    
    Abstract available

  167. TAKEUCHI T, Hattori-Kato M, Okuno Y, Zaitsu M, et al
    Genome-Wide Association Study Adjusted for Occupational and Environmental Factors for Bladder Cancer Susceptibility.
    Genes (Basel). 2022;13.
    PubMed    
    Abstract available

  168. WESSOLLY M, Mairinger FD, Herold T, Hadaschik B, et al
    Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder Cancer.
    Genes (Basel). 2022;13.
    PubMed    
    Abstract available

  169. LAMY L, Thomas J, Leroux A, Bisson JF, et al
    Antitumor Effect and Induced Immune Response Following Exposure of Hexaminolevulinate and Blue Light in Combination with Checkpoint Inhibitor in an Orthotopic Model of Rat Bladder Cancer.
    Biomedicines. 2022;10.
    PubMed    
    Abstract available

  170. MORI K, Matsumoto K, Amano N, Koguchi D, et al
    Expression of Membranous CD155 Is Associated with Aggressive Phenotypes and a Poor Prognosis in Patients with Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  171. HUAN J, Grivas P, Birch J, Hansel DE, et al
    Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  172. BOROWCZAK J, Szczerbowski K, Maniewski M, Zdrenka M, et al
    The Prognostic Role of CDK9 in Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  173. SZKLENER K, Chmiel P, Michalski A, Mandziuk S, et al
    New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  174. RASTEIRO AM, Sa E Lemos E, Oliveira PA, Gil da Costa RM, et al
    Molecular Markers in Urinary Bladder Cancer: Applications for Diagnosis, Prognosis and Therapy.
    Vet Sci. 2022;9.
    PubMed    
    Abstract available

  175. SINHA A, West A, Hayes J, Teoh J, et al
    Methods of Sentinel Lymph Node Detection and Management in Urinary Bladder Cancer-A Narrative Review.
    Curr Oncol. 2022;29:1335-1348.
    PubMed    
    Abstract available

  176. WANG J, Zhao X, Jiang XL, Lu D, et al
    Diagnostic performance of nuclear matrix protein 22 and urine cytology for bladder cancer: A meta-analysis.
    Diagn Cytopathol. 2022 Mar 24. doi: 10.1002/dc.24954.
    PubMed    
    Abstract available

  177. NOTGHI AAA, Hosseini F, Tsogas N
    Severe diffuse proliferative bronchiolitis complicating culture-proven disseminated BCG infection after intravesical instillation for bladder cancer.
    BMJ Case Rep. 2022;15.
    PubMed    
    Abstract available

  178. ROBLES VEGA J, Yankovic Barcelo F
    [Inverted urothelial papilloma of the bladder in an adolescent].
    Andes Pediatr. 2021;92:777-780.
    PubMed    
    Abstract available

  179. WU S, Xu H, Zhang R, Wang X, et al
    Circular RNA circLAMA3 inhibits the proliferation of bladder cancer by directly binding an mRNA.
    Mol Ther Oncolytics. 2022;24:742-754.
    PubMed    
    Abstract available

  180. EL AHANIDI H, El Azzouzi M, Arrouchi H, Alaoui CH, et al
    AKT1 and PIK3CA activating mutations in Moroccan bladder cancer patients biopsies and matched urine.
    Pan Afr Med J. 2022;41:59.
    PubMed    
    Abstract available


  181. [Expert consensus of multi-disciplinary collaboration on bladder-preserving treatment for bladder cancer in China].
    Zhonghua Zhong Liu Za Zhi. 2022;44:209-218.
    PubMed    
    Abstract available

  182. SUN D, Hadjiiski L, Alva A, Zakharia Y, et al
    Computerized Decision Support for Bladder Cancer Treatment Response Assessment in CT Urography: Effect on Diagnostic Accuracy in Multi-Institution Multi-Specialty Study.
    Tomography. 2022;8:644-656.
    PubMed    
    Abstract available

  183. MASUDA T, Tanaka N, Takamatsu K, Hakozaki K, et al
    Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer.
    J Immunother Cancer. 2022;10.
    PubMed    
    Abstract available

  184. MOTTERLE G, Morlacco A, Giovannini G, Vecchiato E, et al
    Role of Renin-Angiotensin System Blockers on BCG Response in Nonmuscle Invasive, High Risk Bladder Cancer.
    Clin Genitourin Cancer. 2022 Feb 24. pii: S1558-7673(22)00044.
    PubMed    
    Abstract available

  185. GAKIS G, Schmid MA, Hassan F, Stenzl A, et al
    The Predictive and Prognostic Value of Precystectomy Serum Gamma-Glutamyltransferase Levels in Patients With Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2022 Feb 24. pii: S1558-7673(22)00041.
    PubMed    
    Abstract available

  186. CHEN YH, Tseng JS
    Concurrent urachal abscess and florid cystitis glandularis masquerading as malignancy: a case report and literature review.
    BMC Surg. 2022;22:105.
    PubMed    
    Abstract available

  187. HUANG KC, Chanda D, McGrath S, Dixit V, et al
    Pharmacological Activation of STING in Bladder Induces Potent Anti-tumor Immunity in Non-Muscle Invasive Murine Bladder Cancer.
    Mol Cancer Ther. 2022 Mar 21. pii: 682323. doi: 10.1158/1535-7163.MCT-21-0780.
    PubMed    
    Abstract available

  188. HONG JH, Tong ZJ, Wei TE, Lu YC, et al
    Cigarette smoke containing acrolein contributes to cisplatin resistance in human bladder cancers through the regulation of HER2 pathway or FGFR3 pathway.
    Mol Cancer Ther. 2022 Mar 21. pii: 682320. doi: 10.1158/1535-7163.MCT-21-0725.
    PubMed    
    Abstract available

  189. CHEN Y, Ji S, Ying J, Sun Y, et al
    KRT6A expedites bladder cancer progression, regulated by miR-31-5p.
    Cell Cycle. 2022 Mar 20:1-12. doi: 10.1080/15384101.2022.2054095.
    PubMed    
    Abstract available

  190. DENG H, Tang F, Zhou M, Shan D, et al
    Identification and Validation of N6-Methyladenosine-Related Biomarkers for Bladder Cancer: Implications for Immunotherapy.
    Front Oncol. 2022;12:820242.
    PubMed    
    Abstract available

  191. SU F, Liu M, Zhang W, Tang M, et al
    Bacillus Calmette-Guerin Treatment Changes the Tumor Microenvironment of Non-Muscle-Invasive Bladder Cancer.
    Front Oncol. 2022;12:842182.
    PubMed    
    Abstract available

  192. DU Y, Sui Y, Cao J, Jiang X, et al
    Dynamic Changes in Myofibroblasts Affect the Carcinogenesis and Prognosis of Bladder Cancer Associated With Tumor Microenvironment Remodeling.
    Front Cell Dev Biol. 2022;10:833578.
    PubMed    
    Abstract available

  193. ZHENG H, Luo W, Li Y, Peng G, et al
    Identification and Development of Inflammatory Response-Related Genes Signature Associated With Prognosis Evaluation and Immune Status of Bladder Cancer.
    Front Cell Dev Biol. 2022;10:837849.
    PubMed    
    Abstract available

  194. BEARDO P, Pinto R, Ayerra H, Aguera J, et al
    Optimizing treatment for non muscle-invasive bladder cancer with an app.
    Actas Urol Esp (Engl Ed). 2022 Mar 17. pii: S2173-5786(22)00026.
    PubMed    
    Abstract available

  195. MAIORANO S, Gulden-Sala W, Gerber B, Ghilardi G, et al
    Anti-PD-L1 monoclonal antibody for the management of chronic disseminated intravascular coagulation secondary to a urothelial carcinoma: a case report.
    J Med Case Rep. 2022;16:113.
    PubMed    
    Abstract available

  196. ZHANG X, Wang Y, Zhang J, Xu X, et al
    Muscle-invasive bladder cancer: pretreatment prediction of response to neoadjuvant chemotherapy with diffusion-weighted MR imaging.
    Abdom Radiol (NY). 2022 Mar 20. pii: 10.1007/s00261-022-03455.
    PubMed    
    Abstract available

  197. HU C, Shang X, Zheng T, Hu X, et al
    Ipatasertib (GDC-0068) and erdafitinib co-treatment for inducing mitochondrial apoptosis through Bim upregulation in bladder cancer cells.
    Biochem Biophys Res Commun. 2022;604:165-171.
    PubMed    
    Abstract available

  198. RAMMANT E, Leung TM, Gore JL, Berry D, et al
    Associations of self-efficacy, social support and coping strategies with health-related quality of life after radical cystectomy for bladder cancer: A cross-sectional study.
    Eur J Cancer Care (Engl). 2022 Mar 18. doi: 10.1111/ecc.13571.
    PubMed    
    Abstract available

  199. DANG E, Vallee A, Lepage-Seydoux C, Sejean K, et al
    Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.
    Curr Oncol. 2022;29:945-955.
    PubMed    
    Abstract available

  200. CALIFANO G, Ouzaid I, Laine-Caroff P, Peyrottes A, et al
    Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art.
    Curr Oncol. 2022;29:687-697.
    PubMed    
    Abstract available

  201. LI X, Wan Z, Liu X, Ou K, et al
    A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy.
    Med Oncol. 2022;39:43.
    PubMed    
    Abstract available

  202. NIEGISCH G, von Amsberg G, Rehlinghaus M, Grunewald CM, et al
    [Metastatic urothelial carcinoma-guideline-based therapy and new options].
    Urologe A. 2022;61:265-272.
    PubMed    
    Abstract available

  203. CHEN S, Cui J, Sun H, Wang W, et al
    "Two-zone and Three-segment" Laparoscopic Radical Cystectomy vs Conventional Laparoscopic Radical Cystectomy for Male Patients With Bladder Urothelial Carcinoma: A Retrospective Analysis.
    Urol J. 2022;19:34-40.
    PubMed    
    Abstract available

  204. LU J, Zhao M, Wu C, Chu C, et al
    Comparison of RNAscope and immunohistochemistry for evaluation of the UPK2 status in urothelial carcinoma tissues.
    Diagn Pathol. 2022;17:10.
    PubMed    
    Abstract available

  205. SAMAL V, Jirasek T, Paldus V, Richter I, et al
    Urachal yolk sac tumor penetrating the bladder as a diagnostic challenge: a case report and review of the literature.
    Diagn Pathol. 2022;17:8.
    PubMed    
    Abstract available

  206. ZHANG J, Bai X, Yuan J, Zhang X, et al
    Bladder paraganglioma: CT and MR imaging characteristics in 16 patients.
    Radiol Oncol. 2021;56:46-53.
    PubMed    
    Abstract available

  207. LUO S, Wang W, Feng J, Li R, et al
    TEX10 Promotes the Tumorigenesis and Radiotherapy Resistance of Urinary Bladder Carcinoma by Stabilizing XRCC6.
    J Immunol Res. 2021;2021:5975893.
    PubMed    
    Abstract available

  208. HAUDEBERT C, Hascoet J, Freton L, Khene ZE, et al
    Cystectomy and ileal conduit for neurogenic bladder: Comparison of the open, laparoscopic and robotic approaches.
    Neurourol Urodyn. 2022;41:601-608.
    PubMed    
    Abstract available

  209. KERIOUI M, Desmee S, Mercier F, Lin A, et al
    Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy.
    ESMO Open. 2022;7:100346.
    PubMed    
    Abstract available

  210. ISHIYAMA Y, Kondo T, Ishihara H, Yoshida K, et al
    Association between Ureteral Clamping Time and Acute Kidney Injury during Robot-Assisted Radical Cystectomy.
    Curr Oncol. 2021;28:4986-4997.
    PubMed    
    Abstract available

  211. SINGH A, Gupta N, Khandakar H, Kaushal S, et al
    Autophagy-associated HMGB-1 as a novel potential circulating non-invasive diagnostic marker for detection of Urothelial Carcinoma of Bladder.
    Mol Cell Biochem. 2022;477:493-505.
    PubMed    
    Abstract available

  212. DONG Y, Zhu GY, Hao L, Liang Q, et al
    High S100A7 expression is associated with early muscle invasion and poor survival in bladder carcinoma.
    Ann Diagn Pathol. 2022;56:151847.
    PubMed    
    Abstract available

  213. WEI H, Wang M, Wasilijiang W, Zhou X, et al
    Propensity score-matched analysis for ileal conduit and orthotopic neobladder intracorporeally accomplished following laparoscopic radical cystectomy.
    Asian J Surg. 2022;45:987-992.
    PubMed    
    Abstract available

  214. LENIS AT, Litwin MS
    Does Artificial Intelligence Meaningfully Enhance Cystoscopy?
    J Natl Cancer Inst. 2022;114:174-175.
    PubMed    


  215. SARIER M, Usta SS, Turgut H, Ozturk SA, et al
    Prognostic value of HPV DNA in Urothelial Carcinoma of the Bladder: A Preliminary Report of 2-Year Follow-up Results.
    Urol J. 2021;19:45-49.
    PubMed    
    Abstract available

  216. KRIMPHOVE MJ, Szymaniak J, Marchese M, Tully KH, et al
    Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy.
    Eur Urol Focus. 2021;7:124-131.
    PubMed    
    Abstract available

  217. LAMBERT E, D'Hondt F, Mazzone E, Vollemaere J, et al
    Time to Move On: The Impending Need for a New Disease-specific Comorbidity Index for Bladder Cancer Patients Undergoing Robot-assisted Radical Cystectomy.
    Eur Urol Focus. 2021;7:139-141.
    PubMed    
    Abstract available

  218. MINNELLA EM, Awasthi R, Bousquet-Dion G, Ferreira V, et al
    Multimodal Prehabilitation to Enhance Functional Capacity Following Radical Cystectomy: A Randomized Controlled Trial.
    Eur Urol Focus. 2021;7:132-138.
    PubMed    
    Abstract available

  219. WU SC, Kwon D, Jue JS, Chen FV, et al
    Androgen Suppression Therapy Is Associated with Lower Recurrence of Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2021;7:142-147.
    PubMed    
    Abstract available

  220. JUBBER I, Pang KH, Groves R, Reed O, et al
    Impact of Anaesthetist Volume on Radical Cystectomy Outcomes.
    Eur Urol Focus. 2021;7:117-123.
    PubMed    
    Abstract available

  221. TOMISAKI I, Harada M, Minato A, Nagata Y, et al
    Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
    Anticancer Res. 2022;42:1629-1634.
    PubMed    
    Abstract available

  222. FURUBAYASHI N, Morokuma F, Tomoda T, Hori Y, et al
    Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study.
    Anticancer Res. 2022;42:1571-1577.
    PubMed    
    Abstract available

  223. SALKINI MW, Yang X, Hashmi FH, Kandzari SJ, et al
    First American Cancer Patient to Receive Dicycloplatin (DCP) Chemotherapy Achieves Remission After Seven Weeks of DCP Capsules - A Case Report.
    Anticancer Res. 2022;42:1339-1344.
    PubMed    
    Abstract available

  224. MAISCH P, Koziarz A, Vajgrt J, Narayan V, et al
    Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.
    BJU Int. 2022 Mar 2. doi: 10.1111/bju.15723.
    PubMed    
    Abstract available

  225. NARII N, Sobue T, Zha L, Kitamura T, et al
    Vegetable and fruit intake and the risk of bladder cancer: Japan Public Health Center-based prospective study.
    Br J Cancer. 2022 Mar 3. pii: 10.1038/s41416-022-01739.
    PubMed    
    Abstract available

  226. KOSHKIN VS, Henderson N, James M, Natesan D, et al
    Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
    Cancer. 2022;128:1194-1205.
    PubMed    
    Abstract available

  227. CRABB SJ, Danson S, Catto JWF, Hussain S, et al
    Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
    Clin Cancer Res. 2021;27:1882-1892.
    PubMed    
    Abstract available

  228. SHENG X, Chen H, Hu B, Yao X, et al
    Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03.
    Clin Cancer Res. 2022;28:489-497.
    PubMed    
    Abstract available

  229. FOERSTER B, Abufaraj M, Matin SF, Azizi M, et al
    Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.
    Eur Urol. 2021;80:507-515.
    PubMed    
    Abstract available

  230. PIAZZA P, Rosiello G, Chacon VT, Puliatti S, et al
    Robot-assisted Cystectomy with Intracorporeal Urinary Diversion After Pelvic Irradiation for Prostate Cancer: Technique and Results from a Single High-volume Center.
    Eur Urol. 2021 Apr 7. pii: S0302-2838(21)00229.
    PubMed    
    Abstract available

  231. WEINSTOCK C, Agrawal S, Chang E
    Optimizing Clinical Trial Design for Patients with Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2022 Mar 15. pii: S0302-2838(22)01655.
    PubMed    


  232. IDE H
    Editorial Comment from Dr Ide to Substratification of patients with highest-risk non-muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A two-center study.
    Int J Urol. 2022 Feb 25. doi: 10.1111/iju.14837.
    PubMed    


  233. KOBAYASHI K, Matsuyama H, Kawai T, Ikeda A, et al
    Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Mar 15. doi: 10.1111/iju.14854.
    PubMed    
    Abstract available

  234. URABE F, Matsuzaki J, Ito K, Takamori H, et al
    Serum microRNA as liquid biopsy biomarker for the prediction of oncological outcomes in patients with bladder cancer.
    Int J Urol. 2022 Mar 14. doi: 10.1111/iju.14858.
    PubMed    
    Abstract available

  235. ZHAO X, Wang Y, Liang C
    Cigarette smoking and risk of bladder cancer: a dose-response meta-analysis.
    Int Urol Nephrol. 2022 Mar 25. pii: 10.1007/s11255-022-03173.
    PubMed    
    Abstract available

  236. PFISTER C, Gravis G, Flechon A, Chevreau C, et al
    Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
    J Clin Oncol. 2022 Mar 7:JCO2102051. doi: 10.1200/JCO.21.02051.
    PubMed    
    Abstract available

  237. SONG Y, Du Y, Qin C, Xu T, et al
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis. Letter.
    J Urol. 2022;207:937.
    PubMed    


  238. GESSNER KH, Siemens DR, Bjurlin MA
    Does Smoking Cessation Reduce Bladder Cancer Recurrence?
    J Urol. 2022 Mar 15:101097JU0000000000002649. doi: 10.1097/JU.0000000000002649.
    PubMed    


  239. YANAGISAWA T, Mori K, Motlagh RS, Kawada T, et al
    En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology.
    J Urol. 2022;207:754-768.
    PubMed    
    Abstract available

  240. MATIN SF, Pierorazio PM, Kleinmann N, Gore JL, et al
    Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
    J Urol. 2022;207:779-788.
    PubMed    
    Abstract available

  241. RICHTER LA, Osazuwa-Peters OL, Routh JC, Handa VL, et al
    Vaginal Complications after Cystectomy: Results from a Medicare Sample.
    J Urol. 2022;207:789-796.
    PubMed    
    Abstract available

  242. AUDENET F, Sotto A, Roumiguie M, Allory Y, et al
    [Guidelines from the cancer (CC-AFU) and infection disease (CI-AFU) committees of the French Association of Urology for the management of adverse events and complications of BCG].
    Prog Urol. 2022;32:165-176.
    PubMed    
    Abstract available

  243. LANNES F, Walz J, Maubon T, Rybikowski S, et al
    Enhanced Recovery after Surgery for Radical Cystectomy Decreases Postoperative Complications at Different Times.
    Urol Int. 2022;106:171-179.
    PubMed    
    Abstract available

  244. SHAO G, Xu C, Liu J, Li X, et al
    Clinical, Pathological, and Prognostic Analysis of Urachal Carcinoma.
    Urol Int. 2022;106:199-208.
    PubMed    
    Abstract available

  245. LIU Z, Zhang P, Wang H, Zheng B, et al
    Raman Spectrum-Based Diagnosis Strategy for Bladder Tumor.
    Urol Int. 2022;106:109-115.
    PubMed    
    Abstract available

  246. CHEN H, Wang M, Weng T, Wei Y, et al
    Prognostic Analysis of Diagnostic Ureteroscopic Biopsy for Intravesical Recurrence of Upper Urinary Tract Urothelial Carcinoma.
    Urol Int. 2022;106:186-194.
    PubMed    
    Abstract available

  247. ADAMCZYK P, Poblocki P, Kadlubowski M, Ostrowski A, et al
    Complication Rate after Radical Cystectomy Depends on the Surgical Technique and Patient's Clinical Status.
    Urol Int. 2022;106:163-170.
    PubMed    
    Abstract available

  248. LEE J, Suh J, Jeong CW, Kwak C, et al
    Efficacy of the Treatment of Intraperitoneal Bladder Perforation during Transurethral Resection of Bladder Tumor with the Urethral Catheter Alone: Retrospective Analysis of over 15 Years Using the Clinical Data Warehouse System.
    Urol Int. 2022;106:138-146.
    PubMed    
    Abstract available

  249. GROBET-JEANDIN E, Wirth GJ, Benamran D, Dupont A, et al
    Substaging of pT1 Urothelial Bladder Carcinoma Predicts Tumor Progression and Overall Survival.
    Urol Int. 2022;106:130-137.
    PubMed    
    Abstract available

  250. GRAFFEILLE V, Verhoest G, Gryn A, Kammerer-Jacquet SF, et al
    Complete Transurethral Resection before Radical Cystectomy May Improve Oncological Outcomes.
    Urol Int. 2022;106:122-129.
    PubMed    
    Abstract available

  251. GHOREIFI A, Djaladat H
    Re: Vejlgaard M, Maibom SL, Stroomberg HV, et al. Long-term Renal Function following Radical Cystectomy for Bladder Cancer. Urology. 2021;S0090-4295(21)01083-9. doi:10.1016/j.urology.2021.11.015.
    Urology. 2022 Feb 25. pii: S0090-4295(22)00146.
    PubMed    


  252. CROGHAN SM, Daniels AE, Kelly C, Fitzgibbon L, et al
    The Pull-through Anastomosis of Ureter to Enteric Conduit (PAUTEC): A Novel Technique for Urinary Diversion.
    Urology. 2021;157:263-268.
    PubMed    
    Abstract available

  253. PACCHETTI A, Pignot G, Le Quellec A, Rybikowski S, et al
    Sexual-Sparing Robot Assisted Radical Cystectomy in Female: A Step-By-Step Guide.
    Urology. 2021;156:322-323.
    PubMed    
    Abstract available

  254. CHANDORA A, Lovin JM, Smith EA
    Inflammatory Myofibroblastic Tumor Presenting as Gross Hematuria in a Pediatric Patient With VACTERL Syndrome Following Bladder Augmentation.
    Urology. 2021;154:268-270.
    PubMed    
    Abstract available

  255. TRAN THT, Melamed J, Deng FM
    Gastric Adenocarcinoma Arising in Gastrocystoplasty.
    Urology. 2021;148:270-273.
    PubMed    
    Abstract available

  256. VEJLGAARD M, Andreas Roder M
    Reply to Djaladat H and Ghoreifi A's Letter-to-the-Editor Re: Vejlgaard M, Maibom SL, Stroomberg HV, et al. Long-term Renal Function Following Radical Cystectomy for Bladder Cancer. Urology. 2021;S0090-4295(21)01083-9. doi:10.1016/j.urology.2021.11.01
    Urology. 2022 Mar 6. pii: S0090-4295(22)00147.
    PubMed    


  257. FANG Q, Zhang X, Nie Q, Hu J, et al
    Improved urine DNA methylation panel for early bladder cancer detection.
    BMC Cancer. 2022;22:237.
    PubMed    
    Abstract available

  258. WANG R, Kang H, Zhang X, Nie Q, et al
    Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.
    BMC Cancer. 2022;22:214.
    PubMed    
    Abstract available

  259. GUAN Z, Sun Y, Mu L, Jiang Y, et al
    Tenascin-C promotes bladder cancer progression and its action depends on syndecan-4 and involves NF-kappaB signaling activation.
    BMC Cancer. 2022;22:240.
    PubMed    
    Abstract available

  260. BHATTACHARJEE S, Sullivan MJ, Wynn RR, Demagall A, et al
    PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth.
    BMC Cancer. 2022;22:312.
    PubMed    
    Abstract available

  261. SUN M, Liu X, Zhao W, Zhang B, et al
    Circ_0058063 contributes to cisplatin-resistance of bladder cancer cells by upregulating B2M through acting as RNA sponges for miR-335-5p.
    BMC Cancer. 2022;22:313.
    PubMed    
    Abstract available

  262. FU Y, Sun S, Bi J, Kong C, et al
    An HDAC9-associated immune-related signature predicts bladder cancer prognosis.
    PLoS One. 2022;17:e0264527.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;